Dosage Recommendations for Off-label Use of Mycophenolate Mofetil in Pediatric Patients with Thalassemia Undergoing Hematopoietic Stem Cell Transplantation: An Approach Based on Population Pharmacokinetic Studies

Overview

Journal Eur J Drug Metab Pharmacokinet

Date 2025 Feb 1

PMID 39891881

Authors

Lu-Lu Niu

Yong-Jun Liu

Yun Wu

Tian-Min Huang

Ting-Qing Wu

Yang Xiao

Xin Chen

Yi-Lin Luo

Tao-Tao Liu

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: As an immunosuppressant, mycophenolate mofetil (MMF) is used to prevent graft versus host disease (GVHD) in patients after hematopoietic stem cell transplantation (HCT). This study aimed to establish a population pharmacokinetic model and simulate the dosage protocol in HCT patients with thalassemia (TM) to fill the gap of lacking MMF dosing regimen.

Methods: The mycophenolic acid (MPA) plasma concentrations were obtained from HCT patients with TM after using MMF. The population pharmacokinetic (PPK) parameters were obtained by NONMEM (Version VII, Level 2.0; ICON Development Solutions, Ellicott City, MD, USA) program. Monte Carlo simulations were used to determine the optimal dosing.

Results: A total of 239 blood samples from 31 pediatric patients were available, the PPK of MPA was described as a two-compartment model. The typical values for MPA clearance (CL), central distribution volume (V), peripheral distribution volume (V), intercompartmental clearance (Q), and absorption rate constant (Ka) were 14.9 L/h, 83.5L, 141L, 3.13 L/h, and 1.37/h respectively. The inter-individual variability (IIV) of CL and V were 35% and 41%, respectively. Simulation results suggested that, as the patient's body surface area (BSA) value increased, MMF dosage initiated from 500 mg twice daily was effective.

Conclusions: A 'tiered' dosage regimen including patient urea and with doses stratified across BSA quartiles, rather than a 'one dose fits all' regimen, would help individualize MMF therapy in this population.

References

Adly A, Ebeid F . Cultural preferences and limited public resources influence the spectrum of thalassemia in Egypt. J Pediatr Hematol Oncol. 2015; 37(4):281-4. DOI: 10.1097/MPH.0000000000000327. View

Au W, Li C, Fang J, Chen G, Sun X, Li C . Assessment of iron overload in very young children with limited thalassemia care resources in South China. Hemoglobin. 2014; 38(2):119-26. DOI: 10.3109/03630269.2014.880715. View

Lee T, von Riedemann S, Tricta F . Cost-utility of chelators in transfusion-dependent β-thalassemia major patients: a review of the pharmacoeconomic literature. Expert Rev Pharmacoecon Outcomes Res. 2014; 14(5):651-60. DOI: 10.1586/14737167.2014.927314. View

Weidlich D, Kefalas P, Guest J . Healthcare costs and outcomes of managing β-thalassemia major over 50 years in the United Kingdom. Transfusion. 2016; 56(5):1038-45. DOI: 10.1111/trf.13513. View

Oellerich M, Shipkova M, Schutz E, Wieland E, Weber L, Tonshoff B . Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant.... Ther Drug Monit. 2000; 22(1):20-6. DOI: 10.1097/00007691-200002000-00004. View

Wieland E, Shipkova M, Schellhaas U, Schutz E, Niedmann P, Armstrong V . Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?. Clin Biochem. 2001; 33(2):107-13. DOI: 10.1016/s0009-9120(99)00101-0. View

Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E . A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004; 34(7):621-5. DOI: 10.1038/sj.bmt.1704647. View

Chao N, Schmidt G, Niland J, Amylon M, Dagis A, Long G . Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. N Engl J Med. 1993; 329(17):1225-30. DOI: 10.1056/NEJM199310213291703. View

Ratanatharathorn V, Nash R, Przepiorka D, Devine S, Klein J, Weisdorf D . Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood. 1998; 92(7):2303-14. View

10.

Bornhauser M, Schuler U, Porksen G, Naumann R, Geissler G, Thiede C . Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation. 1999; 67(4):499-504. DOI: 10.1097/00007890-199902270-00001. View

11.

Niederwieser D, Maris M, Shizuru J, Petersdorf E, Hegenbart U, Sandmaier B . Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can.... Blood. 2002; 101(4):1620-9. DOI: 10.1182/blood-2002-05-1340. View

12.

Kiehl M, Shipkova M, Basara N, Blau I, Schutz E, Armstrong V . Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. Clin Biochem. 2000; 33(3):203-8. DOI: 10.1016/s0009-9120(00)00053-9. View

13.

Jenke A, Renner U, Richte M, Freiberg-Richter J, Platzbecker U, Helwig A . Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant. 2001; 15(3):176-84. DOI: 10.1034/j.1399-0012.2001.150306.x. View

14.

Baudard M, Vincent A, Moreau P, Kergueris M, Harousseau J, Milpied N . Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant. 2002; 30(5):287-95. DOI: 10.1038/sj.bmt.1703633. View

15.

Chen K, Zhang X, Ke X, Du G, Yang K, Zhai S . Individualized Medication of Voriconazole: A Practice Guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society. Ther Drug Monit. 2018; 40(6):663-674. PMC: 6250289. DOI: 10.1097/FTD.0000000000000561. View

16.

Mosteller R . Simplified calculation of body-surface area. N Engl J Med. 1987; 317(17):1098. DOI: 10.1056/NEJM198710223171717. View

17.

Pierrat A, Gravier E, Saunders C, Caira M, Ait-Djafer Z, Legras B . Predicting GFR in children and adults: a comparison of the Cockcroft-Gault, Schwartz, and modification of diet in renal disease formulas. Kidney Int. 2003; 64(4):1425-36. DOI: 10.1046/j.1523-1755.2003.00208.x. View

18.

Zhang F, Chen X, Wu T, Huang N, Li L, Yuan D . Population Pharmacokinetics of Rivaroxaban in Chinese Patients with Non-Valvular Atrial Fibrillation: A Prospective Multicenter Study. Clin Pharmacokinet. 2022; 61(6):881-893. DOI: 10.1007/s40262-022-01108-3. View

19.

Savic R, Jonker D, Kerbusch T, Karlsson M . Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007; 34(5):711-26. DOI: 10.1007/s10928-007-9066-0. View

20.

Bergan S, Brunet M, Hesselink D, Johnson-Davis K, Kunicki P, Lemaitre F . Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2021; 43(2):150-200. DOI: 10.1097/FTD.0000000000000871. View